Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Findlay

Showing results (91-100 of 104) with videos related to

Pageof 11
Sort By:
The Journal of Steroid Biochemistry and Molecular Biology|September 10, 2017
Both ligand and VDR expression levels critically determine the effect of 1α,25-dihydroxyvitamin-D<sub>3</sub> on osteoblast differentiationDongqing Yang, Paul H Anderson, Asiri R Wijenayaka, et al.
Calcified Tissue International|May 26, 2022
A Mild Case of Autosomal Recessive Osteopetrosis Masquerading as the Dominant Form Involving Homozygous Deep Intronic Variations in the CLCN7 GeneJochen G Hofstaetter, Gerald J Atkins, Hajime Kato, et al.
Molecular and Cellular Endocrinology|June 27, 2015
1α,25-dihydroxyvitamin D3 stimulates human SOST gene expression and sclerostin secretionAsiri R Wijenayaka, Dongqing Yang, Matthew Prideaux, et al.
Cancer Medicine|January 11, 2016
Anticancer efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in osteolytic breast cancer murine modelsVasilios Liapis, Irene Zinonos, Agatha Labrinidis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 12, 2009
Apo2L/TRAIL inhibits tumor growth and bone destruction in a murine model of multiple myelomaAgatha Labrinidis, Peter Diamond, Sally Martin, et al.
Cancer Medicine|August 12, 2017
Anticancer efficacy of the hypoxia-activated prodrug evofosfamide is enhanced in combination with proapoptotic receptor agonists against osteosarcomaVasilios Liapis, Aneta Zysk, Mark DeNichilo, et al.
Arthritis Research & Therapy|January 28, 2009
Elevated expression of caspase-3 inhibitors, survivin and xIAP correlates with low levels of apoptosis in active rheumatoid synoviumAnak A S S K Dharmapatni, Malcolm D Smith, David M Findlay, et al.
Biomaterials|June 30, 2006
The correlation of RANK, RANKL and TNFalpha expression with bone loss volume and polyethylene wear debris around hip implantsChristopher A Holding, David M Findlay, Roumen Stamenkov, et al.
Arthritis Research & Therapy|March 26, 2011
TWEAK and Fn14 expression in the pathogenesis of joint inflammation and bone erosion in rheumatoid arthritisAnak A S S K Dharmapatni, Malcolm D Smith, Tania N Crotti, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 5, 2006
TWEAK is a novel arthritogenic mediatorStuart J Perper, Beth Browning, Linda C Burkly, et al.
Pageof 11

Showing results (91-100 of 104) with videos related to

Sort By:
Pageof 11
The Journal of Steroid Biochemistry and Molecular Biology|September 10, 2017
Both ligand and VDR expression levels critically determine the effect of 1α,25-dihydroxyvitamin-D<sub>3</sub> on osteoblast differentiationDongqing Yang, Paul H Anderson, Asiri R Wijenayaka, et al.
Calcified Tissue International|May 26, 2022
A Mild Case of Autosomal Recessive Osteopetrosis Masquerading as the Dominant Form Involving Homozygous Deep Intronic Variations in the CLCN7 GeneJochen G Hofstaetter, Gerald J Atkins, Hajime Kato, et al.
Molecular and Cellular Endocrinology|June 27, 2015
1α,25-dihydroxyvitamin D3 stimulates human SOST gene expression and sclerostin secretionAsiri R Wijenayaka, Dongqing Yang, Matthew Prideaux, et al.
Cancer Medicine|January 11, 2016
Anticancer efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in osteolytic breast cancer murine modelsVasilios Liapis, Irene Zinonos, Agatha Labrinidis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 12, 2009
Apo2L/TRAIL inhibits tumor growth and bone destruction in a murine model of multiple myelomaAgatha Labrinidis, Peter Diamond, Sally Martin, et al.
Cancer Medicine|August 12, 2017
Anticancer efficacy of the hypoxia-activated prodrug evofosfamide is enhanced in combination with proapoptotic receptor agonists against osteosarcomaVasilios Liapis, Aneta Zysk, Mark DeNichilo, et al.
Arthritis Research & Therapy|January 28, 2009
Elevated expression of caspase-3 inhibitors, survivin and xIAP correlates with low levels of apoptosis in active rheumatoid synoviumAnak A S S K Dharmapatni, Malcolm D Smith, David M Findlay, et al.
Biomaterials|June 30, 2006
The correlation of RANK, RANKL and TNFalpha expression with bone loss volume and polyethylene wear debris around hip implantsChristopher A Holding, David M Findlay, Roumen Stamenkov, et al.
Arthritis Research & Therapy|March 26, 2011
TWEAK and Fn14 expression in the pathogenesis of joint inflammation and bone erosion in rheumatoid arthritisAnak A S S K Dharmapatni, Malcolm D Smith, Tania N Crotti, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 5, 2006
TWEAK is a novel arthritogenic mediatorStuart J Perper, Beth Browning, Linda C Burkly, et al.
Pageof 11